Quest Diagnostics Incorporated Common Stock (DGX)
Stock · NYSE · Health Care
$235.03as of 10/16/2026
Price chart
Active signals
DGX Signal Track Record
How signals performed across all stocks →What DGX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 32 | +0.0% | 50% | September 18, 2026 |
| Bollinger Band Breakout | 25 | +1.8% | 60% | August 21, 2026 |
| Bollinger Band Breakdown | 17 | +0.4% | 59% | April 10, 2026 |
| 200-Day Moving Average TouchActive now | 15 | +2.7% | 67% | May 15, 2026 |
| Any 20-session window (baseline) | +1.1% | 57% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About DGX
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and…
- Sector
- Health Care
- Industry
- Medical Specialities
- Employees
- 46,000
- Website
- www.questdiagnostics.com/
Fundamentals
- 1-day range
- $233.81$240.75
- Market cap
- $26.32B
- P/E (trailing)
- 24.67
- P/E (forward)
- 19.40
- EPS (trailing)
- $9.44
- Dividend yield
- 2.10%
- Beta
- 0.56
- Avg. volume
- 1.05M
- Ex-dividend date
- October 6, 2026
- Dividend pay date
- October 21, 2026
How Quest Diagnostics Incorporated Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
15 analyst ratings
Quest Diagnostics Incorporated Common Stock Competitors
Chosen by industry and closest market cap.
- DGXQuest Diagnostics Incorporated Common Stock$235▼ 1.74%Market cap $26.32BP/E 24.67$171.18$248.84
- LHLabcorp Holdings Inc. Common Stock$317.95▼ 2.19%Market cap $25.96BP/E 25.55$244.52$341.8
- ILMNIllumina Inc. Common Stock$262.54▼ 2.01%Market cap $29.25BP/E 48.62$88$309.35
- GHGuardant Health Inc. Common Stock$158.6▼ 4.39%Market cap $21.15BP/E —$61$191.05
- CNCCentene Corporation Common Stock$69.16▼ 1.91%Market cap $31.71BP/E —$31.63$70.37
- NTRANatera Inc. Common Stock$393.44▼ 2.80%Market cap $38.01BP/E —$170.82$437.41
- MOHMolina Healthcare Inc Common Stock$207.36▼ 2.42%Market cap $10.02BP/E 1257.31$121.06$244.89
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| DGX Quest Diagnostics Incorporated Common Stock | $26.32B | 24.67 | $235 | ▼ 1.74% | $171.18$248.84 |
| LH Labcorp Holdings Inc. Common Stock | $25.96B | 25.55 | $317.95 | ▼ 2.19% | $244.52$341.8 |
| ILMN Illumina Inc. Common Stock | $29.25B | 48.62 | $262.54 | ▼ 2.01% | $88$309.35 |
| GH Guardant Health Inc. Common Stock | $21.15B | — | $158.6 | ▼ 4.39% | $61$191.05 |
| CNC Centene Corporation Common Stock | $31.71B | — | $69.16 | ▼ 1.91% | $31.63$70.37 |
| NTRA Natera Inc. Common Stock | $38.01B | — | $393.44 | ▼ 2.80% | $170.82$437.41 |
| MOH Molina Healthcare Inc Common Stock | $10.02B | 1257.31 | $207.36 | ▼ 2.42% | $121.06$244.89 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Quest Diagnostics (NYSE:DGX): A Dividend Quality Pick for Income InvestorsChartMill · 10/9/2026
- Oracle Insider Buys $3.5 Million in Stock Amid OpenAI SwingsYahoo · 10/8/2026
- Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $260benzinga · 10/7/2026
- Natera: Priced To Perfection Amidst Rising Competitive ThreatsSeekingAlpha · 10/7/2026
- Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $260Benzinga · 10/7/2026
- Tuesday's session: gap up and gap down stock in the S&P500 indexChartMill · 10/6/2026
- Quest Diagnostics’ Quarterly Earnings Preview: What You Need to KnowYahoo · 10/5/2026
- Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in FocusYahoo · 10/5/2026
- Dividend Champion, Contender, And Challenger Highlights: Week October 4SeekingAlpha · 10/2/2026
Insider Activity
Insider Actions →- Timothy C. Wentworth · October 1, 2026 · Grant135
- J. E. Davis · September 1, 2026 · Sale10.0K @ $242.72
- Michael E. Prevoznik · August 28, 2026 · Gift1.0K
- Michael E. Prevoznik · August 28, 2026 · Option Exercise22.7K @ $112.17
- Michael E. Prevoznik · August 28, 2026 · Sale430 @ $244.51
- Michael E. Prevoznik · August 28, 2026 · Sale6.2K @ $243.63
- Michael E. Prevoznik · August 28, 2026 · Sale16.0K @ $242.88
- Mark E. Delaney · July 28, 2026 · Sale1.6K @ $235.18
- Robert B. Carter · July 22, 2026 · L11 @ $206.8
- Vicky B. Gregg · July 22, 2026 · Grant72 @ $206.81
- Patrick Plewman · July 22, 2026 · L46 @ $206.81
- Wright Lassiter III · July 22, 2026 · L6 @ $206.81
- Mark E. Delaney · July 22, 2026 · L34 @ $206.81
- Timothy L. Main · July 22, 2026 · L21 @ $206.81
- Sam Samad · July 22, 2026 · Grant102 @ $206.81
Institutional Ownership
March 31, 2026
- Total shares held
- 91.50M
- Total value held
- $16.17B
- Institutional holders
- 1044
- Unknown9.17M
- Unknown7.15M
- Unknown6.30M
- Unknown5.38M
- Unknown4.01M
- Unknown3.09M
- Unknown2.48M
- Unknown2.24M
- Unknown1.95M
- Unknown1.88M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Quest Diagnostics Preps for Q3 Earnings Amid Dividend Focus
Quest Diagnostics is approaching its third-quarter earnings report, with recent coverage highlighting its position as a dividend-paying stock. The company maintains a 2.10% dividend yield and trades at a 24.7 P/E ratio. Analysts currently set an average price target of $251.40, which sits above the current trading range.
Quest Diagnostics Preps for Q3 Earnings Amid Dividend Focus. Quest Diagnostics is approaching its third-quarter earnings report, with recent coverage highlighting its position as a dividend-paying stock. The company maintains a 2.10% dividend yield and trades at a 24.7 P/E ratio. Analysts currently set an average price target of $251.40, which sits above the current trading range.